LNCR
MCID: LNG032
MIFTS: 98

Lung Cancer (LNCR)

Categories: Cancer diseases, Genetic diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lung Cancer

MalaCards integrated aliases for Lung Cancer:

Name: Lung Cancer 57 11 42 75 73 28 5 41 2 14
Non-Small Cell Lung Carcinoma 11 28 5 14 16 71
Lung Carcinoma 11 28 53 5 14 16
Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in 57 12
Lung Cancer, Protection Against 57 5
Adenocarcinoma of Lung, Somatic 57 5
Lung Cancer, Susceptibility to 57 5
Lung Non-Small Cell Carcinoma 11 14
Non-Small Cell Lung Cancer 11 75
Malignant Neoplasm of Lung 42 71
Nonsmall Cell Lung Cancer 57 73
Alveolar Cell Carcinoma 73 28
Carcinoma of Lung 11 71
Lung Neoplasms 42 71
Lung Neoplasm 11 75
Nsclc 11 53
Nonsmall Cell Lung Cancer, Response to Tyrosine Kinase Inhibitor in 57
Nonsmall Cell Lung Cancer, Susceptibility to 57
Nonsmall Cell Lung Cancer, Somatic 57
Primary Malignant Neoplasm of Lung 71
Bronchioloalveolar Adenocarcinoma 71
Carcinoma, Non-Small-Cell Lung 43
Carcinoma Non-Small Cell Lung 53
Cancer, Lung, Non-Small Cell 38
Lung Cancer, Resistance to 57
Malignant Tumor of Lung 42
Adenocarcinoma of Lung 73
Lung Malignant Tumors 42
Respiratory Carcinoma 42
Lung Cancer, Somatic 57
Malignant Lung Tumor 42
Pulmonary Carcinoma 42
Pulmonary Neoplasms 42
Cancer of Bronchus 42
Cancer of the Lung 42
Lung Malignancies 42
Pulmonary Cancer 42
Neoplasm of Lung 28
Lung Carcinomas 14
Cancer of Lung 11
Lung Cancers 14
Cancer, Lung 38
Cancer Lung 53
Lncr 73

Characteristics:


Inheritance:

Somatic mutation 57

OMIM®:

57 (Updated 24-Oct-2022)
Miscellaneous:
genes associated with susceptibility to lung cancer, e.g., faslg , fas , chrna5 , chrna3
genes associated with a protection against lung cancer, e.g., casp8 , cyp2a6
mutations in egfr (131550) are associated with altered response to treatment with tyrosine kinase inhibitors


Classifications:



External Ids:

Disease Ontology 11 DOID:1324 DOID:3905 DOID:3908
OMIM® 57 211980
NCIt 49 C2926 C4878
UMLS 71 C0007120 C0007131 C0024121 more

Summaries for Lung Cancer

MedlinePlus: 41 What is lung cancer? Lung cancer is cancer that forms in tissues of the lung, usually in the cells that line the air passages. It is the leading cause of cancer death in both men and women. There are two main types: small cell lung cancer and non-small cell lung cancer. These two types grow differently and are treated differently. Non-small cell lung cancer is the more common type. Who is at risk for lung cancer? Lung cancer can affect anyone, but there are certain factors that raise your risk of getting it: Smoking. This is the most important risk factor for lung cancer. Tobacco smoking causes about 9 out of 10 cases of lung cancer in men and about 8 out of 10 cases of lung cancer in women. The earlier in life you start smoking, the longer you smoke, and the more cigarettes you smoke per day, the greater your risk of lung cancer. The risk is also greater if you smoke a lot and drink alcohol every day or take beta carotene supplements. If you have quit smoking, your risk will be lower than if you had kept smoking. But you will still have a higher risk than people who never smoked. Secondhand smoke, which is the combination of smoke that comes from a cigarette and smoke breathed out by a smoker. When you inhale it, you are exposed to the same cancer-causing agents as smokers, although in smaller amounts. Family history of lung cancer Being exposed to asbestos, arsenic, chromium, beryllium, nickel, soot, or tar in the workplace Being exposed to radiation, such as from Radiation therapy to the breast or chest Radon in the home or workplace Certain imaging tests such as CT scans HIV infection Air pollution What are the symptoms of lung cancer? Sometimes lung cancer does not cause any signs or symptoms. It may be found during a chest x-ray done for another condition. If you do have symptoms, they may include: Chest pain or discomfort A cough that doesn't go away or gets worse over time Trouble breathing Wheezing Blood in sputum (mucus coughed up from the lungs) Hoarseness Loss of appetite Weight loss for no known reason Fatigue Trouble swallowing Swelling in the face and/or veins in the neck How is lung cancer diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A family history A physical exam Imaging tests, such as a chest x-ray or chest CT scan Lab tests, including tests of your blood and sputum A biopsy of the lung If you do have lung cancer, your provider will do other tests to find out how far it has spread through the lungs, lymph nodes, and the rest of the body. This is called staging. Knowing the type and stage of lung cancer you have helps your provider decide what kind of treatment you need. What are the treatments for lung cancer? For most patients with lung cancer, current treatments do not cure the cancer. Your treatment will depend on which type of lung cancer you have, how far it has spread, your overall health, and other factors. You may get more than one type of treatment. The treatments for small cell lung cancer include: Surgery Chemotherapy Radiation therapy Immunotherapy Laser therapy, which uses a laser beam to kill cancer cells Endoscopic stent placement. An endoscope is a thin, tube-like instrument used to look at tissues inside the body. It may be used to put in a device called a stent. The stent helps to open an airway that has been blocked by abnormal tissue. The treatments for non-small cell lung cancer include: Surgery Radiation therapy Chemotherapy Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells Immunotherapy Laser therapy Photodynamic therapy (PDT), which uses a medicine and a certain type of laser light to kill cancer cells Cryosurgery, which uses an instrument to freeze and destroy abnormal tissue Electrocautery, a treatment that uses a probe or needle heated by an electric current to destroy abnormal tissue Can lung cancer be prevented? Avoiding the risk factors may help to prevent lung cancer: Quitting smoking. If you don't smoke, don't start. Lower your exposure to hazardous substances at work Lower your exposure to radon. Radon tests can show whether your home has high levels of radon. You can buy a test kit yourself or hire a professional to do the test. NIH: National Cancer Institute

MalaCards based summary: Lung Cancer, also known as non-small cell lung carcinoma, is related to lung cancer susceptibility 3 and small cell cancer of the lung, and has symptoms including cough, chest discomfort and weight loss. An important gene associated with Lung Cancer is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Pemetrexed and Erlotinib have been mentioned in the context of this disorder. Affiliated tissues include lung, lungs and brain, and related phenotypes are lung adenocarcinoma and alveolar cell carcinoma

MedlinePlus Genetics: 42 Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor. Lung cancer may not cause signs or symptoms in its early stages. Some people with lung cancer have chest pain, frequent coughing, blood in the mucus, breathing problems, trouble swallowing or speaking, loss of appetite and weight loss, fatigue, or swelling in the face or neck. Additional symptoms can develop if the cancer spreads (metastasizes) into other tissues. Lung cancer occurs most often in adults in their sixties or seventies. Most people who develop lung cancer have a history of long-term tobacco smoking; however, the condition can occur in people who have never smoked.Lung cancer is generally divided into two types, small cell lung cancer and non-small cell lung cancer, based on the size of the affected cells when viewed under a microscope. Non-small cell lung cancer accounts for 85 percent of lung cancer, while small cell lung cancer accounts for the remaining 15 percent.Small cell lung cancer grows quickly and in more than half of cases the cancer has spread beyond the lung by the time the condition is diagnosed. Small cell lung cancer often metastasizes, most commonly to the liver, brain, bones, and adrenal glands (small hormone-producing glands located on top of each kidney). After diagnosis, most people with small cell lung cancer survive for about 1 year; less than seven percent survive 5 years.Non-small cell lung cancer is divided into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell lung carcinoma. Adenocarcinoma arises from the cells that line the small air sacs (alveoli) located throughout the lungs. Squamous cell carcinoma arises from squamous cells that line the passages leading from the windpipe (trachea) to the lungs (bronchi). Large cell carcinoma arises from epithelial cells that line the lungs. Large cell carcinoma encompasses non-small cell lung cancers that do not appear to be adenocarcinomas or squamous cell carcinomas. The 5-year survival rate for people with non-small cell lung cancer is usually between 11 and 17 percent; it can be lower or higher depending on the subtype and stage of the cancer.

OMIM®: 57 Lung cancer is the leading cause of cancer deaths in the U.S. and worldwide. The 2 major forms of lung cancer are nonsmall cell lung cancer and small cell lung cancer (see 182280), which account for 85% and 15% of all lung cancers, respectively. Nonsmall cell lung cancer can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. Cigarette smoking causes all types of lung cancer, but it is most strongly linked with small cell lung cancer and squamous cell carcinoma. Adenocarcinoma is the most common type in patients who have never smoked. Nonsmall cell lung cancer is often diagnosed at an advanced stage and has a poor prognosis (summary by Herbst et al., 2008). (211980) (Updated 24-Oct-2022)

CDC: 2 Cancer is a disease in which cells in the body grow out of control. When cancer starts in the lungs, it is called lung cancer. Lung cancer begins in the lungs and may spread to lymph nodes or other organs in the body, such as the brain. Cancer from other organs also may spread to the lungs. When cancer cells spread from one organ to another, they are called metastases. Lung cancers usually are grouped into two main types called small cell and non-small cell. These types of lung cancer grow differently and are treated differently. Non-small cell lung cancer is more common than small cell lung cancer.

Disease Ontology 11 Lung cancer: A respiratory system cancer that is located in the lung.

Lung carcinoma: A lung cancer that has material basis in abnormally proliferating cells derives from epithelial cells and is located in the lungs and has symptom cough and has symptom chest discomfort or pain and has symptom weight loss and has symptom hemoptysis.

Lung non-small cell carcinoma: A lung carcinoma that is characterized as any type of epithelial lung cancer other than small cell lung carcinoma.

UniProtKB/Swiss-Prot: 73 A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.

Wikipedia 75 Lung cancer: Lung cancer, also known as lung carcinoma (since about 98-99% of all lung cancers are carcinomas), is a... more...

Non-small cell lung cancer: Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small-cell lung... more...

Related Diseases for Lung Cancer

Diseases in the Lung Cancer family:

Lung Carcinoma in Situ

Diseases related to Lung Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2440)
# Related Disease Score Top Affiliating Genes
1 lung cancer susceptibility 3 35.2 PRKN PIK3CA NRAS MET MAP2K1 KRAS
2 small cell cancer of the lung 34.5 PTEN PIK3CA EGFR AKT1
3 adenocarcinoma 34.3 PTEN PIK3CA MET MAP2K1 KRAS ERBB2
4 lung squamous cell carcinoma 34.0 PTEN PIK3CA KRAS EGFR BRAF ALK
5 squamous cell carcinoma 33.9 PTEN PIK3CA NRAS KRAS ERBB2 EGFR
6 breast cancer 33.8 SLC22A18 PTEN PIK3CA NRAS MET MAP2K1
7 colorectal cancer 33.8 PTEN PPP2R1B PIK3CA NRAS MET MAP2K1
8 peripheral nervous system disease 33.6 PTEN PRKN NRAS MAP2K1 KRAS ERCC6
9 gastric cancer 33.5 PTEN PIK3CA NRAS MET MAP2K1 KRAS
10 renal cell carcinoma, nonpapillary 33.5 PTEN PIK3CA NRAS MET MAP2K1 KRAS
11 ovarian cancer 33.4 PTEN PRKN PIK3CA MET MAP2K1 KRAS
12 brain cancer 33.4 PTEN PIK3CA NRAS FASLG EGFR CASP8
13 melanoma 33.4 PTEN PIK3CA NRAS MET MAP2K1 KRAS
14 hepatocellular carcinoma 33.3 PTEN PPP2R1B PIK3CA NRAS MET MAP2K1
15 exanthem 33.3 KRAS ERBB2 EGFR ALK AKT1
16 glioblastoma 33.2 PTEN PIK3CA NRAS MET MAP2K1 KRAS
17 bladder cancer 33.2 PTEN PIK3CA NRAS MET MAP2K1 KRAS
18 leukemia, acute myeloid 33.2 PTEN PIK3CA NRAS MAP2K1 KRAS FASLG
19 pancreatic cancer 33.2 PTEN PIK3CA MET MAP2K1 KRAS FASLG
20 small cell carcinoma 33.1 PTEN EGFR ALK
21 large cell carcinoma 33.1 KRAS ERBB2 EGFR ALK
22 lung large cell carcinoma 33.1 KRAS EGFR ALK
23 neuroblastoma 33.1 PTEN PRKN PIK3CA NRAS MAP2K1 FASLG
24 lung benign neoplasm 33.1 MET KRAS EGFR
25 esophageal cancer 33.1 PTEN PIK3CA KRAS FASLG ERBB2 EGFR
26 squamous cell carcinoma, head and neck 33.1 PTEN PIK3CA MET MAP2K1 FASLG ERBB2
27 lung sarcomatoid carcinoma 32.9 MET KRAS EGFR ALK
28 endometrial cancer 32.9 PTEN PIK3CA NRAS MET MAP2K1 KRAS
29 head and neck cancer 32.9 PTEN PIK3CA KRAS ERCC6 ERBB2 EGFR
30 lung non-squamous non-small cell carcinoma 32.9 KRAS ERBB2 EGFR ALK
31 in situ carcinoma 32.8 PTEN PIK3CA KRAS ERBB2 EGFR AKT1
32 gastrointestinal stromal tumor 32.8 PTEN PIK3CA NRAS MET MAP2K1 KRAS
33 colonic benign neoplasm 32.7 PTEN PIK3CA KRAS ERBB2 EGFR BRAF
34 nervous system disease 32.7 PTEN PRKN PIK3CA MET MAP2K1 KRAS
35 leukemia, chronic lymphocytic 32.7 PTEN NRAS KRAS ERBB2 EGFR CASP8
36 bronchus cancer 32.6 ERBB2 EGFR ALK
37 myeloma, multiple 32.6 PIK3CA NRAS MET KRAS FASLG CASP8
38 rhabdomyosarcoma 32.6 SLC22A18 PTEN PIK3CA NRAS MET MAP2K1
39 gastric adenocarcinoma 32.5 PTEN PIK3CA NRAS MET MAP2K1 KRAS
40 paronychia 32.5 MAP3K8 KRAS ERBB2 EGFR ALK
41 malignant pleural mesothelioma 32.4 PTEN MET EGFR AKT1
42 lynch syndrome 32.4 PTEN PIK3CA KRAS ERCC6 ERBB2 EGFR
43 adenosquamous carcinoma 32.4 KRAS EGFR ALK
44 sarcoma 32.4 PIK3CA MET MAP3K8 KRAS BRAF ALK
45 cervical cancer 32.4 PTEN PPP2R1B PIK3CA IRF1 ERBB2 CASP8
46 adenoma 32.4 PIK3CA KRAS BRAF AKT1
47 skin carcinoma 32.4 PTEN NRAS ERCC6 ERBB2 EGFR AKT1
48 skin disease 32.4 PTEN PIK3CA NRAS KRAS ERCC6 ERBB2
49 acute promyelocytic leukemia 32.3 PTEN PIK3CA NRAS MAP2K1 KRAS IRF1
50 cholangiocarcinoma 32.3 PTEN PIK3CA MET KRAS ERBB2 EGFR

Graphical network of the top 20 diseases related to Lung Cancer:



Diseases related to Lung Cancer

Symptoms & Phenotypes for Lung Cancer

Human phenotypes related to Lung Cancer:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 lung adenocarcinoma 30 HP:0030078
2 alveolar cell carcinoma 30 HP:0006519

Symptoms via clinical synopsis from OMIM®:

57 (Updated 24-Oct-2022)
Respiratory Lung:
alveolar cell carcinoma
adenocarcinoma of lung
nonsmall cell lung cancer

Neoplasia:
alveolar cell carcinoma
adenocarcinoma of lung
nonsmall cell lung cancer

Clinical features from OMIM®:

211980 (Updated 24-Oct-2022)

Symptoms:

11
  • cough
  • chest discomfort
  • weight loss
  • hemoptysis

UMLS symptoms related to Lung Cancer:


coughing; dyspnea; fever; hemoptysis; snoring

GenomeRNAi Phenotypes related to Lung Cancer according to GeneCards Suite gene sharing:

25 (show top 50) (show all 78)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 11.12 BRAF EGFR KRAS PIK3CA
2 Decreased viability GR00055-A-2 11.12 BRAF EGFR KRAS PIK3CA
3 Decreased viability GR00055-A-3 11.12 KRAS
4 Decreased viability GR00106-A-0 11.12 KRAS
5 Decreased viability GR00107-A-1 11.12 MAP2K1
6 Decreased viability GR00221-A-1 11.12 EGFR KRAS PIK3CA AKT1 NRAS ALK
7 Decreased viability GR00221-A-2 11.12 KRAS PIK3CA AKT1 MAP3K8
8 Decreased viability GR00221-A-3 11.12 AKT1 ERBB2 MAP2K1 MAP3K8 NRAS
9 Decreased viability GR00221-A-4 11.12 BRAF EGFR PIK3CA AKT1 ERBB2 MAP3K8
10 Decreased viability GR00249-S 11.12 BRAF AKT1 ALK
11 Decreased viability GR00301-A 11.12 BRAF KRAS MAP3K8
12 Decreased viability GR00342-S-1 11.12 MAP3K8
13 Decreased viability GR00342-S-2 11.12 MAP3K8
14 Decreased viability GR00342-S-3 11.12 MAP3K8
15 Decreased viability GR00381-A-1 11.12 BRAF KRAS
16 Decreased viability GR00402-S-2 11.12 PIK3CA MAP3K8
17 Increased shRNA abundance (Z-score > 2) GR00366-A-10 10.82 MET
18 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.82 CYP2A6
19 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.82 MET
20 Increased shRNA abundance (Z-score > 2) GR00366-A-108 10.82 MAP3K8
21 Increased shRNA abundance (Z-score > 2) GR00366-A-119 10.82 MET
22 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.82 KRAS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.82 EGFR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.82 BRAF
25 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.82 PTEN
26 Increased shRNA abundance (Z-score > 2) GR00366-A-158 10.82 IRF1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.82 PTEN
28 Increased shRNA abundance (Z-score > 2) GR00366-A-160 10.82 IRF1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.82 ERBB2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-165 10.82 MAP3K8
31 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.82 ERBB2 PTEN
32 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.82 PRKN
33 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.82 CYP2A6
34 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10.82 IRF1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.82 MET
36 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10.82 MET
37 Increased shRNA abundance (Z-score > 2) GR00366-A-200 10.82 IRF1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-201 10.82 MET
39 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.82 ERBB2
40 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.82 EGFR
41 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.82 AKT1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.82 EGFR PTEN
43 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.82 KRAS
44 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.82 MAP3K8
45 Increased shRNA abundance (Z-score > 2) GR00366-A-27 10.82 IRF1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.82 CYP2A6 IRF1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.82 NRAS
48 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.82 ERBB2
49 Increased shRNA abundance (Z-score > 2) GR00366-A-38 10.82 MET
50 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.82 MAP3K8

MGI Mouse Phenotypes related to Lung Cancer:

45 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.54 AKT1 ALK BRAF CASP8 CYP2A6 EGFR
2 neoplasm MP:0002006 10.51 AKT1 ALK BRAF CASP8 EGFR ERBB2
3 growth/size/body region MP:0005378 10.45 AKT1 ALK BRAF CASP8 EGFR ERBB2
4 nervous system MP:0003631 10.44 AKT1 ALK BRAF CASP8 EGFR ERBB2
5 normal MP:0002873 10.42 AKT1 ALK BRAF EGFR ERBB2 FASLG
6 endocrine/exocrine gland MP:0005379 10.38 AKT1 ALK BRAF CASP8 EGFR ERBB2
7 cellular MP:0005384 10.38 AKT1 BRAF CASP8 EGFR ERBB2 ERCC6
8 cardiovascular system MP:0005385 10.33 AKT1 BRAF CASP8 EGFR ERBB2 FASLG
9 muscle MP:0005369 10.32 AKT1 BRAF CASP8 EGFR ERBB2 ERCC6
10 liver/biliary system MP:0005370 10.27 AKT1 BRAF CASP8 EGFR ERCC6 FASLG
11 embryo MP:0005380 10.26 AKT1 BRAF CASP8 EGFR ERBB2 KRAS
12 digestive/alimentary MP:0005381 10.25 BRAF EGFR ERBB2 FASLG KRAS MAP2K1
13 immune system MP:0005387 10.25 AKT1 BRAF CASP8 EGFR ERCC6 FASLG
14 skeleton MP:0005390 10.2 AKT1 ALK BRAF EGFR ERBB2 ERCC6
15 renal/urinary system MP:0005367 10.19 BRAF CASP8 EGFR FASLG IRF1 KRAS
16 limbs/digits/tail MP:0005371 10.17 BRAF EGFR ERBB2 ERCC6 KRAS MET
17 reproductive system MP:0005389 10.15 AKT1 ALK BRAF EGFR ERBB2 FASLG
18 respiratory system MP:0005388 10.14 AKT1 ALK BRAF CASP8 EGFR ERBB2
19 craniofacial MP:0005382 10.1 BRAF EGFR ERBB2 KRAS MAP2K1 MET
20 pigmentation MP:0001186 10.09 ALK BRAF EGFR KRAS NRAS PTEN
21 vision/eye MP:0005391 10 ALK BRAF EGFR ERCC6 FASLG KRAS
22 hematopoietic system MP:0005397 9.93 AKT1 BRAF CASP8 EGFR ERBB2 ERCC6
23 mortality/aging MP:0010768 9.89 AKT1 ALK BRAF CASP8 EGFR ERBB2
24 integument MP:0010771 9.5 AKT1 ALK BRAF CASP8 EGFR ERBB2

Drugs & Therapeutics for Lung Cancer

Drugs for Lung Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 923)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pemetrexed Approved, Investigational Phase 4 150399-23-8, 137281-23-3 60843 446556 135565230
2
Erlotinib Approved, Investigational Phase 4 183319-69-9, 183321-74-6 176870
3
Carboplatin Approved Phase 4 41575-94-4 10339178 38904
4
Terbutaline Approved Phase 4 23031-25-6 5403
5
Ipratropium Approved, Experimental Phase 4 22254-24-6, 60205-81-4 657309 3746
6
Nicotine Approved Phase 4 54-11-5 942 89594
7
Gemcitabine Approved Phase 4 95058-81-4, 122111-03-9 60750
8
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
9
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
10
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
11
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
12
Remifentanil Approved Phase 4 132875-61-7 60815
13
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
14
Budesonide Approved Phase 4 51333-22-3 5281004 40000 63006
15
Amifostine Approved, Investigational Phase 4 20537-88-6 2141
16
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
17
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
18
Desflurane Approved Phase 4 57041-67-5 42113
19
Caffeine Approved Phase 4 58-08-2 2519
20
Tropisetron Approved, Investigational Phase 4 105826-92-4, 89565-68-4 656665
21
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760
22
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
23
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
24
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
25
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
26
Cisatracurium Approved Phase 4 96946-41-7 62887
27
Magnesium sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9
28
Clonidine Approved Phase 4 4205-91-8, 4205-90-7 2803 20179
29
Scopolamine Approved, Investigational Phase 4 51-34-3 153311 3000322
30
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
31
Olanzapine Approved, Investigational Phase 4 132539-06-1 135398745 4585
32
Acetaminophen Approved Phase 4 103-90-2 1983
33
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
34
Zoledronic acid Approved Phase 4 118072-93-8 68740
35
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
36
Vemurafenib Approved Phase 4 918504-65-1 42611257
37
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
38
Docetaxel Approved, Investigational Phase 4 114977-28-5 148124
39
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
40
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
41
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
42
Ondansetron Approved Phase 4 99614-02-5 4595
43
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
44
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
45
Histamine Approved, Investigational Phase 4 51-45-6 774
46
Fosaprepitant Approved Phase 4 172673-20-0 219090 135413538
47
Crofelemer Approved Phase 4 33507-63-0, 148465-45-6 36511 44359816
48
Aprepitant Approved, Investigational Phase 4 170729-80-3 6918365 135413536
49
Ibandronate Approved, Investigational Phase 4 114084-78-5 60852
50
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693

Interventional clinical trials:

(show top 50) (show all 9214)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Randomized, Open-label, Parallel-group Study of Paclitaxel Liposome and Cisplatin Compared With Gemcitabine and Cisplatin as First-line Therapy in Advanced Squamous Non-Small-Cell Lung Cancer Unknown status NCT02996214 Phase 4 Paclitaxel Liposome;Gemcitabine;Cisplatin
2 Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride in in Combination With EC/EP Unknown status NCT03890055 Phase 4 Anlotinib Hydrochloride
3 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial Unknown status NCT00724581 Phase 4 Amiodarone
4 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
5 A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
6 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
7 Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen: A Prospective, Open, One-arm Clinical Study Unknown status NCT03792503 Phase 4 Apatinib;Pemetrexed
8 PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
9 A Phase Ⅳ,Open,Multicenter,Single Arm Study to Evaluate the Efficacy of the Combination Conmana With Thalidomide in Patients With NSCLC(Non-Small-Cell-Lung-Cancer) Unknown status NCT02778893 Phase 4 Conmana;Thalidomide
10 The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (Ⅲ A / Ⅲ B) ) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
11 Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin)
12 A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
13 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
14 Efficacy of Nebulized Pulmicort Respules on Post Operation Pulmonary Complication During Pulmonary Single Lobectomy Surgery in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
15 High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE): a Randomized, Open-label Study Unknown status NCT02404675 Phase 4 icotinib
16 Evaluation of the Efficacy of Domestic Gefitinib Tablets in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Using a Multicenter, Randomized, Positive Drug Gefitinib Pharmacodynamics and Pharmacodynamics Unknown status NCT03264794 Phase 4 Gefitinib Tab (CTTQ),First medication;Gefitinib Tab (CTTQ),From the 8th day of trial;Gefitinib tablets (Yi Ruisha),First medication;Gefitinib Tab 250 MG(CTTQ),From the 8th day of trial.
17 The Randomized Controlled Clinical Trial of Kushen Injection Reducing Radiotherapy Related Adverse Reactions in Lung Cancer Unknown status NCT02346318 Phase 4 Compound Kushen Injection
18 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
19 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
20 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting Programmed Cell Death 1 (PD-1) Unknown status NCT03313544 Phase 4 Nivolumab
21 Safety Evaluation of Dexmedetomidine Monitored Anesthesia Care for Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
22 Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
23 A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
24 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy
25 An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation Unknown status NCT01646450 Phase 4 Icotinib
26 Randomized Open-label Study of the Impact of Prolonged Systemic Corticosteroid Therapy on the Course and Relapse Risk of Checkpoint Inhibitor Interstitial Lung Disease (Pneumonitis) Related to the Treatment of Solid Tumors With Anti-programmed-death Type 1 Receptor or Ligand Antibodies Unknown status NCT04036721 Phase 4 Prolonged glucocorticosteroid (prednisone) regimen;Short glucocorticosteroid (prednisone) regimen
27 A Double Blind , Randomized, Multicenter Study of Second Line Treatment of Endostar(rh Recombined Endostatin)With Single Docetaxel In NSCLC Patients Unknown status NCT00813332 Phase 4 Endostar(rh recombinant endostatin) plus Docetaxel;Placebo plus Docetaxel
28 A Study to Evaluate the Efficacy and Safety of Anlotinib Plus Pemetrexed as the 1-line Treatment of Patients With Platinum Intolerant Advanced Non-squamous NSCLC, With Pemetrexed Control. Unknown status NCT03768037 Phase 4 Anlotinib plus Pemetrexed;Pemetrexed
29 Elderly Cancer PatIents Treated for Advanced or Metastatic Melanoma or NSCLC, Safety and qualiTy of Life Under immunOtheraPies: a Phase IV Trial Unknown status NCT03673332 Phase 4 immune-checkpoint inhibitors therapies
30 An Open, Single-arm, Multi-center Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy Unknown status NCT03778853 Phase 4 Anlotinib Hydrochloride
31 An Open, Single-arm, Multi-center Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line Chemotherapy Unknown status NCT03755869 Phase 4 Anlotinib
32 Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
33 Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
34 A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
35 Safety Study of Nivolumab for Selected Advanced Malignancies in India Completed NCT03444766 Phase 4 Nivolumab
36 ONCOXIN® and Quality of Life in Cancer Patients in a Real World Setting Study Completed NCT03550482 Phase 4
37 Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
38 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
39 An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First Line Treatment in Caucasian Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed NCT01203917 Phase 4 Gefitinib
40 A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy Completed NCT00770588 Phase 4 Gefitinib;Placebo
41 A Prospective, Multicenter, Phase-IV Clinical Trial to Assess Safety of Osimertinib in Indian Adult Patients With Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-positive Non-small Cell Lung Cancer (NSCLC). Completed NCT03853551 Phase 4 Osimertinib
42 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
43 Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response Completed NCT03655834 Phase 4 Pemetrexed
44 Modafinil for the Treatment of Fatigue in Lung Cancer: a Multicentre, Randomised, Double-blinded, Placebo-controlled Trial Completed NCT00829322 Phase 4 Modafinil;Placebo
45 A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
46 Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer - A Randomized, Controlled Trial Completed NCT01741506 Phase 4 Dalteparin (Fragmin®)
47 Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic Completed NCT00440960 Phase 4 propofol;midazolam;alfentanil;lidocaine
48 An Open Label, Single-arm Phase IV Study to Assess the Efficacy and Safety of Afatinib as Second-line Therapy for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harbouring an EGFR Mutation (Del19 or L858R) Who Have Failed First-line Treatment With Platinum-based Chemotherapy Completed NCT02208843 Phase 4 Afatinib
49 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
50 Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]

Search NIH Clinical Center for Lung Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Afatinib
afatinib dimaleate
Carboplatin
Carmustine
ceritinib
Cholecalciferol
Cisplatin
CISPLATIN PWDR
crizotinib
Cyclophosphamide
docetaxel
erlotinib
Etoposide
etoposide phosphate
gefitinib
hydroxyurea
Ifosfamide
irinotecan
Irinotecan hydrochloride
Lomustine
Methotrexate
Methotrexate Sodium
Paclitaxel
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
Teniposide
Topotecan
Topotecan Hydrochloride
trametinib
Vinblastine
Vinblastine Sulfate
vinorelbine
Vinorelbine tartrate

Cochrane evidence based reviews: carcinoma, non-small-cell lung

Genetic Tests for Lung Cancer

Genetic tests related to Lung Cancer:

# Genetic test Affiliating Genes
1 Lung Carcinoma 28 FASLG
2 Non-Small Cell Lung Carcinoma 28
3 Neoplasm of Lung 28
4 Alveolar Cell Carcinoma 28
5 Lung Cancer 28 BRAF CASP8 CYP2A6 EGFR ERBB2 ERCC6 FASLG IRF1 KRAS PIK3CA PRKN SLC22A18

Anatomical Context for Lung Cancer

Organs/tissues related to Lung Cancer:

FMA: Lung, Lungs
MalaCards : Lung, Brain, Lymph Node, Breast, T Cells, Bone, Liver
ODiseA: Respiratory System-Lung, Respiratory System

Publications for Lung Cancer

Articles related to Lung Cancer:

(show top 50) (show all 70592)
# Title Authors PMID Year
1
Screening for epidermal growth factor receptor mutations in lung cancer. 53 62 57 5
19692684 2009
2
LKB1 modulates lung cancer differentiation and metastasis. 53 62 57 5
17676035 2007
3
Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. 53 62 57 5
15937082 2005
4
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. 53 62 57 5
15118073 2004
5
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. 53 57 5
15329413 2004
6
A major lung cancer susceptibility locus maps to chromosome 6q23-25. 62 57 5
15272417 2004
7
Lung cancer: intragenic ERBB2 kinase mutations in tumours. 62 57 5
15457249 2004
8
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. 62 57 5
15118125 2004
9
Missense mutations of the BRAF gene in human lung adenocarcinoma. 53 57 5
12460919 2002
10
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. 62 57 5
11745231 2001
11
CYP2A6 gene deletion reduces susceptibility to lung cancer. 53 57 5
10441482 1999
12
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. 57 5
19692680 2009
13
Somatic mutations affect key pathways in lung adenocarcinoma. 57 5
18948947 2008
14
A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. 57 5
17450141 2007
15
High frequency of mutations of the PIK3CA gene in human cancers. 57 5
15016963 2004
16
Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. 57 5
10217419 1999
17
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. 53 62 5
20022809 2010
18
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 53 62 5
19794967 2009
19
A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells. 53 62 5
19513541 2009
20
Genetic predictors of MEK dependence in non-small cell lung cancer. 53 62 5
19010912 2008
21
A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib. 53 62 5
18628075 2008
22
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. 53 62 5
18458038 2008
23
Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. 53 62 5
18611285 2008
24
DNA methylation markers and early recurrence in stage I lung cancer. 53 62 57
18337602 2008
25
EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy. 53 62 5
17653080 2008
26
Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. 53 62 5
18199554 2008
27
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. 53 62 5
18089823 2007
28
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. 53 62 57
17625570 2007
29
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. 53 62 57
17463250 2007
30
PIK3CA mutation status in Japanese lung cancer patients. 53 62 5
16930767 2006
31
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. 53 62 5
16906227 2006
32
EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. 53 62 5
16863509 2006
33
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. 53 62 5
16638863 2006
34
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. 53 62 5
16533793 2006
35
Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. 53 62 5
16011858 2005
36
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. 53 62 5
16043828 2005
37
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. 53 62 5
15753357 2005
38
Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. 53 62 57
12802680 2003
39
BRAF and RAS mutations in human lung cancer and melanoma. 53 62 5
12460918 2002
40
Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. 53 62 57
10580025 1999
41
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. 62 5
35658005 2022
42
Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid. 62 5
31396478 2019
43
In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. 62 5
26515464 2015
44
Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases. 62 5
26372703 2015
45
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. 62 5
26051236 2015
46
EGFR T790M resistance mutation in non small-cell lung carcinoma. 62 5
25668228 2015
47
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. 62 5
25923549 2015
48
Rociletinib in EGFR-mutated non-small-cell lung cancer. 62 5
25923550 2015
49
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. 62 57
25301630 2014
50
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. 62 5
24893891 2014

Variations for Lung Cancer

ClinVar genetic disease variations for Lung Cancer:

5 (show top 50) (show all 406)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CASP8 NM_001228.4(CASP8):c.-937_-932del DEL Protective
7763 rs3834129 GRCh37: 2:202097532-202097537
GRCh38: 2:201232809-201232814
2 CYP2A6 CYP2A6*4A DEL Protective
16970 GRCh37:
GRCh38:
3 BMP2 NC_000020.10:g.6767111A>G SNV Confers Sensitivity
996153 GRCh37: 20:6767111-6767111
GRCh38: 20:6786464-6786464
4 SMAD9 NM_001127217.3(SMAD9):c.-186-7998T>C SNV Confers Sensitivity
996154 GRCh37: 13:37462010-37462010
GRCh38: 13:36887873-36887873
5 SMAD3 NM_005902.4(SMAD3):c.207-32200C>T SNV Confers Sensitivity
996155 GRCh37: 15:67425033-67425033
GRCh38: 15:67132695-67132695
6 SMAD4 NM_005359.6(SMAD4):c.*5131A>G SNV Confers Sensitivity
327175 rs12456284 GRCh37: 18:48609968-48609968
GRCh38: 18:51083598-51083598
7 ERCC6, ERCC6-PGBD3, PGBD3 NM_000124.4(ERCC6):c.1357C>T (p.Arg453Ter) SNV Pathogenic
1703 rs121917902 GRCh37: 10:50732119-50732119
GRCh38: 10:49524073-49524073
8 BRAF NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala) SNV Pathogenic
Pathogenic
Pathogenic
Likely Pathogenic
Likely Pathogenic
Likely Pathogenic
13971 rs121913355 GRCh37: 7:140481402-140481402
GRCh38: 7:140781602-140781602
9 BRAF NM_004333.6(BRAF):c.1415A>G (p.Tyr472Cys) SNV Pathogenic
375949 rs1057519719 GRCh37: 7:140481393-140481393
GRCh38: 7:140781593-140781593
10 BRAF NM_004333.6(BRAF):c.1397G>T (p.Gly466Val) SNV Pathogenic
Pathogenic/Likely Pathogenic
Pathogenic/Likely Pathogenic
Likely Pathogenic
Likely Pathogenic
13967 rs121913351 GRCh37: 7:140481411-140481411
GRCh38: 7:140781611-140781611
11 PALB2 NM_024675.4(PALB2):c.79G>T (p.Glu27Ter) SNV Pathogenic
241570 rs878855122 GRCh37: 16:23649420-23649420
GRCh38: 16:23638099-23638099
12 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) SNV Pathogenic
Pathogenic
Likely Pathogenic
Likely Pathogenic
13652 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
13 BRAF NM_004333.6(BRAF):c.1789C>G (p.Leu597Val) SNV Pathogenic
Pathogenic
13969 rs121913369 GRCh37: 7:140453146-140453146
GRCh38: 7:140753346-140753346
14 BRAF NM_004333.6(BRAF):c.1391G>T (p.Gly464Val) SNV Pathogenic
40364 rs121913348 GRCh37: 7:140481417-140481417
GRCh38: 7:140781617-140781617
15 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) SNV Pathogenic
Pathogenic
Likely Pathogenic
13961 rs113488022 GRCh37: 7:140453136-140453136
GRCh38: 7:140753336-140753336
16 KRAS NM_004985.5(KRAS):c.37G>T (p.Gly13Cys) SNV Pathogenic
Pathogenic
Pathogenic
45123 rs121913535 GRCh37: 12:25398282-25398282
GRCh38: 12:25245348-25245348
17 KRAS NM_004985.5(KRAS):c.38G>A (p.Gly13Asp) SNV Pathogenic
Pathogenic
Pathogenic
12580 rs112445441 GRCh37: 12:25398281-25398281
GRCh38: 12:25245347-25245347
18 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Pathogenic
Pathogenic
Likely Pathogenic
Likely Pathogenic
13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
19 KRAS NM_004985.5(KRAS):c.35G>A (p.Gly12Asp) SNV Pathogenic
Pathogenic
Pathogenic
Likely Pathogenic
Not Provided
12582 rs121913529 GRCh37: 12:25398284-25398284
GRCh38: 12:25245350-25245350
20 PIK3CA NM_006218.4(PIK3CA):c.1624G>A (p.Glu542Lys) SNV Pathogenic
Likely Pathogenic
Likely Pathogenic
Likely Pathogenic
31944 rs121913273 GRCh37: 3:178936082-178936082
GRCh38: 3:179218294-179218294
21 MAP2K1 NM_002755.4(MAP2K1):c.167A>C (p.Gln56Pro) SNV Pathogenic
375978 rs1057519729 GRCh37: 15:66727451-66727451
GRCh38: 15:66435113-66435113
22 MAP2K1 NM_002755.4(MAP2K1):c.171G>T (p.Lys57Asn) SNV Pathogenic
Likely Pathogenic
Likely Pathogenic
223140 rs869025608 GRCh37: 15:66727455-66727455
GRCh38: 15:66435117-66435117
23 EGFR NM_005228.5(EGFR):c.2573T>G (p.Leu858Arg) SNV Pathogenic
Pathogenic
Likely Pathogenic
Likely Pathogenic
16609 rs121434568 GRCh37: 7:55259515-55259515
GRCh38: 7:55191822-55191822
24 AKT1 NM_001382430.1(AKT1):c.49G>A (p.Glu17Lys) SNV Pathogenic
Likely Pathogenic
13983 rs121434592 GRCh37: 14:105246551-105246551
GRCh38: 14:104780214-104780214
25 MAP2K1 NM_002755.4(MAP2K1):c.199G>A (p.Asp67Asn) SNV Pathogenic
40781 rs727504317 GRCh37: 15:66727483-66727483
GRCh38: 15:66435145-66435145
26 PTEN NM_000314.8(PTEN):c.697C>T (p.Arg233Ter) SNV Pathogenic
7813 rs121909219 GRCh37: 10:89717672-89717672
GRCh38: 10:87957915-87957915
27 BRAF NM_004333.6(BRAF):c.721A>C (p.Thr241Pro) SNV Pathogenic
29807 rs387906661 GRCh37: 7:140501351-140501351
GRCh38: 7:140801551-140801551
28 BRAF NM_004333.6(BRAF):c.722C>T (p.Thr241Met) SNV Pathogenic
29805 rs387906660 GRCh37: 7:140501350-140501350
GRCh38: 7:140801550-140801550
29 ERCC6 NM_000124.4(ERCC6):c.2203C>T (p.Arg735Ter) SNV Pathogenic
1701 rs121917901 GRCh37: 10:50686483-50686483
GRCh38: 10:49478437-49478437
30 BRCA1 NM_007294.4(BRCA1):c.5503C>T (p.Arg1835Ter) SNV Pathogenic
55601 rs41293465 GRCh37: 17:41197784-41197784
GRCh38: 17:43045767-43045767
31 EGFR-AS1, EGFR NM_005228.5(EGFR):c.2369C>T (p.Thr790Met) SNV Pathogenic
Pathogenic/Likely Pathogenic
Likely Pathogenic
16613 rs121434569 GRCh37: 7:55249071-55249071
GRCh38: 7:55181378-55181378
32 NRAS NM_002524.5(NRAS):c.34G>A (p.Gly12Ser) SNV Pathogenic
Pathogenic
Pathogenic
177778 rs121913250 GRCh37: 1:115258748-115258748
GRCh38: 1:114716127-114716127
33 EGFR NM_005228.5(EGFR):c.2155G>A (p.Gly719Ser) SNV Pathogenic
Pathogenic
Likely Pathogenic
Likely Pathogenic
16612 rs28929495 GRCh37: 7:55241707-55241707
GRCh38: 7:55174014-55174014
34 KRAS NM_004985.5(KRAS):c.182A>G (p.Gln61Arg) SNV Pathogenic
Pathogenic
45115 rs121913240 GRCh37: 12:25380276-25380276
GRCh38: 12:25227342-25227342
35 NRAS NM_002524.5(NRAS):c.35G>A (p.Gly12Asp) SNV Pathogenic
Pathogenic
39648 rs121913237 GRCh37: 1:115258747-115258747
GRCh38: 1:114716126-114716126
36 PIK3CA NM_006218.4(PIK3CA):c.3073A>G (p.Thr1025Ala) SNV Pathogenic
45467 rs397517202 GRCh37: 3:178952018-178952018
GRCh38: 3:179234230-179234230
37 EGFR NM_005228.5(EGFR):c.988G>A (p.Glu330Lys) SNV Pathogenic
560008 rs139429793 GRCh37: 7:55223621-55223621
GRCh38: 7:55155928-55155928
38 ERCC6 NM_000124.4(ERCC6):c.2830-2A>G SNV Pathogenic
190163 rs373227647 GRCh37: 10:50680518-50680518
GRCh38: 10:49472472-49472472
39 PRKN NM_004562.3(PRKN):c.823C>T (p.Arg275Trp) SNV Pathogenic
7050 rs34424986 GRCh37: 6:162206852-162206852
GRCh38: 6:161785820-161785820
40 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr) SNV Pathogenic
Pathogenic
Likely Pathogenic
39705 rs121913281 GRCh37: 3:178952084-178952084
GRCh38: 3:179234296-179234296
41 KRAS NM_004985.5(KRAS):c.458A>T (p.Asp153Val) SNV Pathogenic
12587 rs104894360 GRCh37: 12:25362838-25362838
GRCh38: 12:25209904-25209904
42 NRAS NM_002524.5(NRAS):c.181C>A (p.Gln61Lys) SNV Pathogenic
Likely Pathogenic
73058 rs121913254 GRCh37: 1:115256530-115256530
GRCh38: 1:114713909-114713909
43 BRAF NM_004333.6(BRAF):c.1790T>G (p.Leu597Arg) SNV Pathogenic
13968 rs121913366 GRCh37: 7:140453145-140453145
GRCh38: 7:140753345-140753345
44 BRAF NM_004333.6(BRAF):c.1801A>G (p.Lys601Glu) SNV Pathogenic
Likely Pathogenic
13966 rs121913364 GRCh37: 7:140453134-140453134
GRCh38: 7:140753334-140753334
45 BRAF NM_004333.6(BRAF):c.1794_1796dup (p.Thr599dup) DUP Pathogenic
162793 rs727502902 GRCh37: 7:140453138-140453139
GRCh38: 7:140753338-140753339
46 BRAF NM_004333.6(BRAF):c.1405_1407del (p.Gly469del) DEL Pathogenic
44802 rs397516890 GRCh37: 7:140481401-140481403
GRCh38: 7:140781601-140781603
47 BRAF NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly) SNV Pathogenic
Likely Pathogenic
13972 rs121913338 GRCh37: 7:140453154-140453154
GRCh38: 7:140753354-140753354
48 BRAF NM_004333.6(BRAF):c.1405_1406delinsTT (p.Gly469Leu) INDEL Pathogenic
375950 rs1057519720 GRCh37: 7:140481402-140481403
GRCh38: 7:140781602-140781603
49 EGFR-AS1, EGFR NM_005228.5(EGFR):c.2310_2311insGGGTTG (p.Asp770_Asn771insGlyLeu) INSERT Pathogenic
45257 rs397517111 GRCh37: 7:55249012-55249013
GRCh38: 7:55181319-55181320
50 EGFR-AS1, EGFR NM_005228.5(EGFR):c.2312_2314dup (p.Asn771_Pro772insHis) DUP Pathogenic
45258 rs397517112 GRCh37: 7:55249013-55249014
GRCh38: 7:55181320-55181321

UniProtKB/Swiss-Prot genetic disease variations for Lung Cancer:

73
# Symbol AA change Variation ID SNP ID
1 BRAF p.Gly466Val VAR_018512 rs121913351
2 BRAF p.Leu597Arg VAR_018513 rs121913366
3 MXRA5 p.Ser862Asn VAR_072408
4 SLC22A18 p.Ser233Phe VAR_024062 rs121909071

Cosmic variations for Lung Cancer:

8 (show top 50) (show all 35906)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263727 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 72
2 COSM95442728 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 72
3 COSM85262562 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 72
4 COSM85263435 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 72
5 COSM95441934 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.599+122C>T p.? 3:50342996-50342996 72
6 COSM143112283 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 72
7 COSM101592316 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 72
8 COSM101606460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 72
9 COSM101614868 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 72
10 COSM101585076 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 72
11 COSM101614672 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 72
12 COSM143112460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 72
13 COSM143103178 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 72
14 COSM101592471 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 72
15 COSM102032968 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7406A>C p.? 16:72958371-72958371 72
16 COSM102040512 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1439C>A p.S480* 16:72798501-72798501 72
17 COSM102043690 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8060C>T p.S2687L 16:72787474-72787474 72
18 COSM87286137 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 72
19 COSM102031099 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7886C>A p.A2629D 16:72787648-72787648 72
20 COSM149303773 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 72
21 COSM149318853 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.331G>A p.E111K 16:72959815-72959815 72
22 COSM149318882 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 72
23 COSM149268808 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 72
24 COSM102042371 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-6501G>T p.? 16:72957466-72957466 72
25 COSM102037223 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7773G>T p.? 16:72958738-72958738 72
26 COSM149260552 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10961C>T p.S3654L 16:72787315-72787315 72
27 COSM87273791 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2755G>T p.G919C 16:72950930-72950930 72
28 COSM87274581 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 72
29 COSM87284855 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4834G>C p.E1612Q 16:72797848-72797848 72
30 COSM149303017 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 72
31 COSM102022101 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6240C>G p.F2080L 16:72793700-72793700 72
32 COSM102032971 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7046G>T p.? 16:72958011-72958011 72
33 COSM87287980 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 72
34 COSM149309579 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 72
35 COSM102028052 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2928G>C p.Q976H 16:72797012-72797012 72
36 COSM149263533 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1910G>A p.G637E 16:72958236-72958236 72
37 COSM149322707 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 72
38 COSM87279299 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6293C>T p.S2098L 16:72796389-72796389 72
39 COSM149327483 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1582C>T p.Q528* 16:72958564-72958564 72
40 COSM87274095 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.628G>T p.G210C 16:72959518-72959518 72
41 COSM102037726 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.689G>T p.C230F 16:72889748-72889748 72
42 COSM102022617 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.13G>T p.G5C 16:72950930-72950930 72
43 COSM149265687 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8982C>G p.F2994L 16:72793700-72793700 72
44 COSM87281915 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6289T>G p.F2097V 16:72796393-72796393 72
45 COSM149269636 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 72
46 COSM102047871 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3243C>G p.I1081M 16:72796697-72796697 72
47 COSM149263422 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 72
48 COSM102041859 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1021C>T p.P341S 16:72811678-72811678 72
49 COSM87272331 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 72
50 COSM149290601 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10628C>A p.A3543D 16:72787648-72787648 72

Copy number variations for Lung Cancer from CNVD:

6 (show top 50) (show all 2490)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13366 1 1 16100000 Deletion Lung cancer
2 13395 1 1 2300000 Gain Lung cancer
3 13734 1 1 23800000 Deletion Lung cancer
4 13820 1 1 7200000 Amplification TP73 Lung cancer
5 13987 1 102200000 107200000 Loss Lung cancer
6 14041 1 103360338 103520551 Copy number Lung cancer
7 14049 1 103536651 169070598 Copy number Lung cancer
8 14407 1 107915304 108309068 Gain or loss VAV3 Lung cancer
9 14593 1 109594163 109619901 Copy number CELSR2 Lung cancer
10 14851 1 110683467 110690826 Copy number RBM15 Lung cancer
11 14877 1 11089178 11245151 Copy number MTOR Lung cancer
12 15005 1 111800000 116100000 Deletion MAGI3 Lung cancer
13 15023 1 111886577 112057624 Gain or loss RAP1A Lung cancer
14 15119 1 112811562 112865428 Gain or loss WNT2B Lung cancer
15 15157 1 113045271 113051548 Gain or loss RHOC Lung cancer
16 15169 1 113054138 113059473 Gain or loss PPM1J Lung cancer
17 15226 1 1136568 1139375 Amplification TNFRSF4 Lung cancer
18 15236 1 113734997 114030068 Copy number MAGI3 Lung cancer
19 15325 1 114736921 114855304 Copy number TRIM33 Lung cancer
20 15385 1 115048600 115061038 Copy number NRAS Lung cancer
21 15386 1 115048600 115061038 Copy number NRAS Lung cancer
22 15445 1 115630059 115682380 Gain or loss NGF Lung cancer
23 15530 1 11657123 11674265 Gain or loss MAD2L2 Lung cancer
24 15914 1 120255698 120413799 Copy number NOTCH2 Lung cancer
25 15980 1 120700000 184000000 Gain ABL2 Non-small cell lung cancer
26 16423 1 124300000 247249719 Amplification Non-small cell lung cancer
27 16774 1 13731635 13731966 Deletion PRDM2 Non-small cell lung cancer
28 17335 1 142400000 241700000 Gain Non-small cell lung cancer
29 17545 1 143388229 143787436 Gain or loss PDE4DIP Lung cancer
30 18154 1 144225552 144227256 Gain or loss GNRHR2 Lung cancer
31 18182 1 144287344 144297903 Gain or loss PIAS3 Lung cancer
32 18354 1 145093308 145110753 Copy number PRKAB2 Lung cancer
33 18411 1 145479805 145564639 Gain or loss BCL9 Lung cancer
34 18946 1 148000000 149600000 Amplification ARNT Lung cancer
35 18957 1 148000000 149600000 Gain MCL1 Lung cancer
36 18959 1 148000899 148065680 Amplification ARNT Lung cancer
37 19019 1 148178855 148249310 Gain or loss OTUD7B Lung cancer
38 19034 1 148256282 148256554 Amplification MLLT11 Lung cancer
39 19180 1 149048809 149115810 Gain or loss ARNT Lung cancer
40 19404 1 150112683 150148737 Gain or loss THEM4 Lung cancer
41 20067 1 15300000 153300000 Amplification ECM1 Non-small cell lung cancer
42 20068 6 25834269 25834769 Amplification H2AC1 Non-small cell lung cancer
43 20074 1 15300000 153300000 Gain S100A1 Non-small cell lung cancer
44 20081 1 15300000 163800000 Amplification H2BC21 Non-small cell lung cancer
45 20580 1 153201397 153213464 Gain or loss SHC1 Lung cancer
46 20651 1 153424923 153429324 Gain or loss MUC1 Lung cancer
47 20775 1 154291228 154296003 Gain or loss LAMTOR2 Lung cancer
48 20890 1 155003897 155037233 Gain or loss PRCC Lung cancer
49 20912 1 155052165 155118266 Gain or loss NTRK1 Lung cancer
50 20922 1 155077288 155095290 Copy number INSRR Lung cancer

Expression for Lung Cancer

LifeMap Discovery
Genes differentially expressed in tissues of Lung Cancer patients vs. healthy controls: 35 (show top 50) (show all 216)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 SFTPC surfactant protein C Lung - 6.58 0.000
2 CLDN18 claudin 18 Lung - 6.41 0.000
3 ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide Lung - 6.18 0.000
4 KRT6A keratin 6A Lung + 5.85 0.000
5 AGER advanced glycosylation end-product specific receptor Lung - 5.70 0.000
6 MMP12 matrix metallopeptidase 12 Lung + 5.63 0.000
7 CLIC5 chloride intracellular channel 5 Lung - 5.51 0.000
8 AQP4 aquaporin 4 Lung - 5.29 0.000
9 CYP4B1 cytochrome P450 family 4 subfamily B member 1 Lung - 5.27 0.000
10 SPRR1B small proline rich protein 1B Lung + 5.25 0.000
11 AKR1B10 aldo-keto reductase family 1 member B10 Lung + 5.16 0.000
12 MMP1 matrix metallopeptidase 1 Lung + 5.11 0.000
13 KRT6B keratin 6B Lung + 5.10 0.000
14 TMEM100 transmembrane protein 100 Lung - 5.07 0.000
15 FABP4 fatty acid binding protein 4 Lung - 5.03 0.000
16 GKN2 gastrokine 2 Lung - 4.99 0.000
17 FAM107A family with sequence similarity 107 member A Lung - 4.95 0.000
18 MT1M metallothionein 1M Lung - 4.94 0.000
19 CPB2 carboxypeptidase B2 Lung - 4.88 0.000
20 KRT17 keratin 17 Lung + 4.87 0.000
21 S100A2 S100 calcium binding protein A2 Lung + 4.84 0.000
22 SERPINB5 serpin family B member 5 Lung + 4.83 0.000
23 GJB2 gap junction protein beta 2 Lung + 4.78 0.000
24 SPRR1A small proline rich protein 1A Lung + 4.77 0.000
25 KRT5 keratin 5 Lung + 4.73 0.000
26 GPM6A glycoprotein M6A Lung - 4.71 0.000
27 GREM1 gremlin 1, DAN family BMP antagonist Lung + 4.69 0.000
28 COL11A1 collagen type XI alpha 1 chain Lung + 4.68 0.000
29 TOP2A DNA topoisomerase II alpha Lung + 4.66 0.000
30 GJB6 gap junction protein beta 6 Lung + 4.62 0.000
31 PEBP4 phosphatidylethanolamine binding protein 4 Lung - 4.61 0.000
32 DST dystonin Lung + 4.52 0.000
33 TNNC1 troponin C1, slow skeletal and cardiac type Lung - 4.46 0.000
34 DSG3 desmoglein 3 Lung + 4.45 0.000
35 VEGFD vascular endothelial growth factor D Lung - 4.43 0.000
36 MCEMP1 mast cell expressed membrane protein 1 Lung - 4.43 0.000
37 CLEC3B C-type lectin domain family 3 member B Lung - 4.42 0.000
38 SPRR3 small proline rich protein 3 Lung + 4.36 0.000
39 FCN3 ficolin 3 Lung - 4.34 0.000
40 PSAT1 phosphoserine aminotransferase 1 Lung + 4.33 0.000
41 SPP1 secreted phosphoprotein 1 Lung + 4.32 0.000
42 KRT15 keratin 15 Lung + 4.30 0.000
43 KRT14 keratin 14 Lung + 4.30 0.000
44 GPX2 glutathione peroxidase 2 Lung + 4.29 0.000
45 SLC2A1 solute carrier family 2 member 1 Lung + 4.27 0.000
46 WIF1 WNT inhibitory factor 1 Lung - 4.27 0.000
47 SOX2 SRY-box transcription factor 2 Lung + 4.25 0.000
48 ABCA8 ATP binding cassette subfamily A member 8 Lung - 4.25 0.000
49 ANLN anillin, actin binding protein Lung + 4.21 0.000
50 SFTPD surfactant protein D Lung - 4.20 0.000
Search GEO for disease gene expression data for Lung Cancer.

Pathways for Lung Cancer



Pathways directly related to Lung Cancer:

# Pathway Source
1 Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1) Reactome 66

Pathways related to Lung Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 182)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.12 AKT1 CASP8 FASLG IRF1 KRAS MAP2K1
2
Show member pathways
14 PTEN NRAS MET MAP3K8 MAP2K1 KRAS
3
Show member pathways
13.95 PTEN PPP2R1B NRAS MET MAP3K8 MAP2K1
4 13.91 PTEN PPP2R1B PIK3CA NRAS MET MAP2K1
5
Show member pathways
13.9 SLC22A18 PTEN PPP2R1B PIK3CA NRAS MET
6
Show member pathways
13.86 AKT1 ALK BRAF EGFR ERBB2 KRAS
7
Show member pathways
13.78 PPP2R1B NRAS MET MAP2K1 KRAS FASLG
8
Show member pathways
13.71 NRAS MET MAP2K1 KRAS ERBB2 EGFR
9
Show member pathways
13.67 PPP2R1B PIK3CA NRAS MET MAP3K8 MAP2K1
10
Show member pathways
13.65 PTEN PRKN PPP2R1B PIK3CA NRAS MAP3K8
11
Show member pathways
13.63 PTEN PIK3CA NRAS MET MAP3K8 MAP2K1
12
Show member pathways
13.57 AKT1 ALK EGFR ERBB2 FASLG KRAS
13
Show member pathways
13.55 PTEN PIK3CA NRAS MAP2K1 KRAS EGFR
14
Show member pathways
13.51 PTEN PPP2R1B PIK3CA NRAS MET MAP2K1
15
Show member pathways
13.48 AKT1 ALK EGFR ERBB2 KRAS MAP2K1
16
Show member pathways
13.48 PPP2R1B PIK3CA NRAS MAP3K8 MAP2K1 KRAS
17
Show member pathways
13.46 PTEN NRAS MET KRAS FASLG ERBB2
18
Show member pathways
13.43 AKT1 ALK BRAF CASP8 EGFR ERBB2
19
Show member pathways
13.24 AKT1 BRAF EGFR KRAS MAP2K1 MET
20
Show member pathways
13.23 PTEN PPP2R1B PIK3CA MET ERBB2 EGFR
21
Show member pathways
13.22 PPP2R1B NRAS MET MAP2K1 KRAS EGFR
22
Show member pathways
13.11 PTEN PPP2R1B NRAS MAP2K1 KRAS BRAF
23
Show member pathways
13.1 PTEN PPP2R1B PIK3CA NRAS MET MAP2K1
24
Show member pathways
13.09 PTEN PIK3CA MAP2K1 IRF1 FASLG EGFR
25
Show member pathways
13.07 PPP2R1B PIK3CA NRAS MAP2K1 KRAS BRAF
26
Show member pathways
13.04 PTEN PIK3CA NRAS MAP2K1 KRAS BRAF
27
Show member pathways
13.03 PIK3CA NRAS MAP2K1 KRAS FASLG BRAF
28
Show member pathways
13.03 AKT1 BRAF EGFR KRAS MAP2K1 MET
29
Show member pathways
13.03 PIK3CA NRAS MAP3K8 MAP2K1 KRAS FASLG
30
Show member pathways
13.01 PIK3CA NRAS MAP2K1 KRAS CASP8 BRAF
31
Show member pathways
12.99 AKT1 BRAF EGFR ERBB2 KRAS MAP2K1
32
Show member pathways
12.94 AKT1 CASP8 KRAS MAP2K1 MET NRAS
33
Show member pathways
12.92 PTEN PIK3CA MET MAP2K1 EGFR AKT1
34
Show member pathways
12.92 PIK3CA NRAS MAP3K8 MAP2K1 KRAS BRAF
35
Show member pathways
12.89 NRAS KRAS FASLG EGFR CASP8
36 12.87 PTEN PIK3CA MET MAP2K1 EGFR AKT1
37
Show member pathways
12.87 PTEN PPP2R1B PIK3CA MET ERBB2 EGFR
38
Show member pathways
12.86 NRAS MAP2K1 KRAS EGFR BRAF AKT1
39
Show member pathways
12.85 NRAS MAP2K1 KRAS EGFR BRAF AKT1
40
Show member pathways
12.85 NRAS MAP2K1 KRAS FASLG EGFR BRAF
41 12.83 PPP2R1B PIK3CA NRAS MET MAP2K1 KRAS
42
Show member pathways
12.8 PPP2R1B NRAS MAP2K1 KRAS BRAF
43
Show member pathways
12.79 PPP2R1B NRAS MAP3K8 MAP2K1 KRAS FASLG
44
Show member pathways
12.78 PIK3CA NRAS KRAS ERBB2 EGFR AKT1
45
Show member pathways
12.77 PPP2R1B PIK3CA NRAS MET MAP2K1 KRAS
46
Show member pathways
12.76 AKT1 BRAF KRAS MAP2K1 NRAS
47
Show member pathways
12.76 EGFR IRF1 KRAS MAP2K1 MAP3K8
48
Show member pathways
12.75 PPP2R1B PIK3CA NRAS MAP2K1 KRAS BRAF
49
Show member pathways
12.68 PTEN PIK3CA MAP3K8 MAP2K1 AKT1
50
Show member pathways
12.66 PTEN PIK3CA MET MAP2K1 ERBB2 BRAF

GO Terms for Lung Cancer

Biological processes related to Lung Cancer according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.41 AKT1 ALK BRAF EGFR ERBB2 FASLG
2 positive regulation of gene expression GO:0010628 10.26 AKT1 BRAF ERBB2 ERCC6 KRAS MAP2K1
3 negative regulation of neuron apoptotic process GO:0043524 10.21 PRKN PIK3CA KRAS BRAF
4 positive regulation of protein phosphorylation GO:0001934 10.2 KRAS ERBB2 EGFR BRAF AKT1
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 10.19 MET ERBB2 EGFR ALK
6 protein phosphorylation GO:0006468 10.18 AKT1 ALK BRAF EGFR ERBB2 MAP2K1
7 nervous system development GO:0007399 10.14 PTEN MET ERCC6 ERBB2 ALK AKT1
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 10.13 AKT1 BRAF EGFR PIK3CA
9 positive regulation of kinase activity GO:0033674 10.1 MET ERBB2 EGFR ALK
10 positive regulation of protein tyrosine kinase activity GO:0061098 10.07 ERCC6 EGFR ALK
11 cellular response to epidermal growth factor stimulus GO:0071364 10.05 ERBB2 EGFR AKT1
12 T cell costimulation GO:0031295 10.04 AKT1 MAP3K8 PIK3CA
13 epidermal growth factor receptor signaling pathway GO:0007173 10.01 PIK3CA EGFR BRAF AKT1
14 phosphatidylinositol 3-kinase signaling GO:0014065 9.92 PTEN PIK3CA ERBB2 AKT1
15 peptidyl-tyrosine phosphorylation GO:0018108 9.85 ALK BRAF EGFR ERBB2 MAP2K1 MET
16 response to UV-A GO:0070141 9.84 EGFR AKT1
17 insulin-like growth factor receptor signaling pathway GO:0048009 9.81 PIK3CA MAP2K1 AKT1
18 cellular response to decreased oxygen levels GO:0036294 9.73 PTEN AKT1
19 multicellular organism development GO:0007275 9.73 MET ERBB2 EGFR ALK
20 MAPK cascade GO:0000165 9.73 NRAS MAP3K8 MAP2K1 KRAS EGFR BRAF
21 positive regulation of miRNA maturation GO:1903800 9.61 MAP2K1 EGFR
22 regulation of axon regeneration GO:0048679 9.56 PTEN MAP2K1 BRAF
23 phosphorylation GO:0016310 9.4 PIK3CA MET MAP3K8 MAP2K1 ERBB2 EGFR

Molecular functions related to Lung Cancer according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.43 PTEN PRKN MET KRAS ERBB2 EGFR
2 ATP binding GO:0005524 10.43 AKT1 ALK BRAF EGFR ERBB2 ERCC6
3 transferase activity GO:0016740 10.02 PRKN PIK3CA MET MAP3K8 MAP2K1 ERBB2
4 protein kinase activity GO:0004672 10 MET MAP3K8 MAP2K1 ERBB2 EGFR BRAF
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.97 ALK EGFR ERBB2 MET
6 protein tyrosine kinase activity GO:0004713 9.9 ALK BRAF EGFR ERBB2 MAP2K1 MET
7 MAP kinase kinase kinase activity GO:0004709 9.88 MAP3K8 EGFR BRAF
8 nitric-oxide synthase regulator activity GO:0030235 9.8 EGFR AKT1
9 protein serine/threonine kinase activator activity GO:0043539 9.78 PIK3CA MAP2K1 KRAS
10 kinase activity GO:0016301 9.7 PIK3CA MET MAP3K8 MAP2K1 ERBB2 EGFR
11 nucleotide binding GO:0000166 9.4 PIK3CA NRAS MET MAP3K8 MAP2K1 KRAS

Sources for Lung Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....